Summit Therapeutics Files 8-K: Material Agreement & Exhibits
Ticker: SMMT · Form: 8-K · Filed: Aug 11, 2025 · CIK: 1599298
| Field | Detail |
|---|---|
| Company | Summit Therapeutics Inc. (SMMT) |
| Form Type | 8-K |
| Filed Date | Aug 11, 2025 |
| Risk Level | medium |
| Pages | 4 |
| Reading Time | 5 min |
| Key Dollar Amounts | $0.01, $360,000,000, $90.0 million, $45.8 million |
| Sentiment | neutral |
Sentiment: neutral
Topics: material-agreement, filing, exhibits
TL;DR
Summit Therapeutics filed an 8-K on Aug 11, 2025, reporting a material definitive agreement and financial exhibits.
AI Summary
On August 11, 2025, Summit Therapeutics Inc. filed an 8-K report. The filing indicates an entry into a material definitive agreement and includes financial statements and exhibits. The company is incorporated in Delaware and its principal executive offices are located in Miami, Florida.
Why It Matters
This 8-K filing signals a significant development for Summit Therapeutics Inc., potentially involving a new material agreement that could impact its business operations and financial standing.
Risk Assessment
Risk Level: medium — The filing of a material definitive agreement suggests a significant event, but the lack of specific details about the agreement's nature and terms necessitates a medium risk assessment.
Key Numbers
- 001-36866 — SEC File Number (Identifies the company's filing with the SEC.)
- 37-1979717 — IRS Employer Identification No. (Company's tax identification number.)
Key Players & Entities
- Summit Therapeutics Inc. (company) — Registrant
- August 11, 2025 (date) — Date of Report
- Miami, FL (location) — Principal Executive Offices
- Delaware (location) — State of Incorporation
FAQ
What is the nature of the material definitive agreement entered into by Summit Therapeutics Inc. on August 11, 2025?
The filing does not specify the nature of the material definitive agreement, only that one was entered into.
What are the key financial statements and exhibits included in this 8-K filing?
The filing indicates that financial statements and exhibits are included, but their specific content is not detailed in the provided text.
Where are Summit Therapeutics Inc.'s principal executive offices located?
Summit Therapeutics Inc.'s principal executive offices are located at 601 Brickell Key Drive, Suite 1000, Miami, FL 33131.
When was Summit Therapeutics Inc. incorporated?
Summit Therapeutics Inc. was incorporated in Delaware.
What is the SEC file number for Summit Therapeutics Inc.?
The SEC file number for Summit Therapeutics Inc. is 001-36866.
Filing Stats: 1,173 words · 5 min read · ~4 pages · Grade level 12.1 · Accepted 2025-08-11 16:51:33
Key Financial Figures
- $0.01 — ange on Which Registered Common stock, $0.01 par value per share SMMT The Nasdaq
- $360,000,000 — the Sales Agent, by up to an additional $360,000,000. At the time of the Original Distribu
- $90.0 million — n stock in an aggregate amount of up to $90.0 million (the "May 2024 Prospectus Supplement"),
- $45.8 million — Prospectus Supplement"), approximately $45.8 million of which remained available for sale by
Filing Documents
- d56029d8k.htm (8-K) — 33KB
- d56029dex11.htm (EX-1.1) — 238KB
- d56029dex12.htm (EX-1.2) — 15KB
- d56029dex51.htm (EX-5.1) — 8KB
- g56029g0811154707234.jpg (GRAPHIC) — 5KB
- g56029g0811154707520.jpg (GRAPHIC) — 6KB
- g56029g0811154707674.jpg (GRAPHIC) — 3KB
- 0001193125-25-178022.txt ( ) — 496KB
- smmt-20250811.xsd (EX-101.SCH) — 3KB
- smmt-20250811_lab.xml (EX-101.LAB) — 18KB
- smmt-20250811_pre.xml (EX-101.PRE) — 11KB
- d56029d8k_htm.xml (XML) — 4KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits Exhibit Number Description 1.1 Distribution Agreement, dated May 13, 2024, by and between Summit Therapeutics Inc. and J.P. Morgan Securities LLC 1.2 Amendment to Distribution Agreement, dated August 11, 2025, by and between Summit Therapeutics Inc. and J.P. Morgan Securities LLC 5.1 Opinion of Baker & Hostetler LLP 23.1 Consent of Baker & Hostetler LLP (included in Exhibit 5.1) 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized. SUMMIT THERAPEUTICS INC. Date: August 11, 2025 By: /s/ Manmeet S. Soni Chief Operating Officer, Chief Financial Officer and Director (Principal Financial Officer)